



HAL
open science

Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study

Paul Breillat, Marie Jachiet, Yoan Ditchi, Cédric Lenormand, Nathalie Costedoat-Chalumeau, Alexis Mathian, Philippe Moguelet, Paul Duriez, Marten Trendelenburg, Uyen Huynh-Do, et al.

► To cite this version:

Paul Breillat, Marie Jachiet, Yoan Ditchi, Cédric Lenormand, Nathalie Costedoat-Chalumeau, et al.. Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study. *Rheumatology*, 2023, 62 (6), pp.2189-2196. 10.1093/rheumatology/keac566 . hal-04233679

HAL Id: hal-04233679

<https://hal.science/hal-04233679v1>

Submitted on 17 Jan 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicenter cohort study

Paul Breillat¹; Marie Jachiet²; Yoan Ditchi³; Cédric Lenormand⁴; Nathalie Costedoat-Chalumeau⁵; Alexis Mathian¹; Philippe Moguelet³; Paul Duriez³; Marten Trendelenburg⁶; Uyen Huynh-Do⁷; Carlo Chizzolini^{8,9}; Clément Beuvon¹⁰; Frederique Roy-Peaud¹⁰; Jean-David Bouaziz²; Annick Barbaud¹¹; Camille Francès¹¹; Arsène Mékinian¹²; Olivier Fain¹²; Zahir Amoura¹; François Chasset¹¹ for EMSED study group (Etude des maladies systémiques en dermatologie) and the Swiss SLE Cohort Study (SSCS).

1 Sorbonne Université, Faculté de médecine, AP-HP, Service de Médecine interne 2, Hôpital Pitié Salpêtrière, Paris, France

2 Université de Paris, Faculté de médecine, AP-HP, Service de Dermatologie, Hôpital Saint-Louis, Paris, France

3 Sorbonne Université, Faculté de médecine, AP-HP, Service d'anatomo-pathologie, Hôpital Saint Antoine, Paris, France

4 Service de Dermatologie, Hôpital Civil - Hôpitaux Universitaires de Strasbourg, Strasbourg, France

5 Université de Paris cité, Faculté de médecine, AP-HP, Service de Médecine interne, Hôpital Cochin, Paris, France

6 Laboratory for Clinical Immunology, Department of Biomedicine and Division of Internal Medicine, University Hospital of Basel, Switzerland

1
2
3 7 Division of Nephrology and Hypertension, Inselspital, Bern University Hospital,
4
5 Switzerland

6
7
8 8 Pathology and Immunology, Centre Médical Universitaire, School of Medicine, Geneva,
9
10 Switzerland

11
12
13 9 Department of Pathology and Immunology, School of Medicine, Geneva, Switzerland

14
15
16 10 Service de Médecine interne, Hôpitaux Universitaires de Poitiers, Poitiers, France

17
18
19 11 Sorbonne Université, Faculté de médecine, AP-HP, Service de Dermatologie et
20
21 Allergologie, Hôpital Tenon, Paris, France

22
23
24 12 Sorbonne Université, Faculté de médecine, AP-HP, Service de Médecine interne, Hôpital
25
26 Saint-Antoine, Paris, France

27
28
29
30 **Corresponding author and reprint request:**

31
32
33 François Chasset, MD, PhD

34
35 AP-HP, Service de Dermatologie et d'Allergologie, Sorbonne Université, Hôpital Tenon

36
37 4 Rue de la Chine 75970 Paris CEDEX 20, France

38
39 Email: francois.chasset@aphp.fr

40
41
42
43
44 **Abbreviations**

45
46 ACR, American College of Rheumatology

47
48
49 ADICAP, Association pour le Développement de l'Informatique en Cytologie et Anatomie
50
51 Pathologie

52
53
54 ANCAs, anti-neutrophil cytoplasmic autoantibodies

55
56
57 APS, Antiphospholipid Syndrome
58
59
60

1
2
3 CRP, C-reactive protein
4
5

6 CV, cutaneous vasculitis
7
8

9 ELISA, enzyme-linked immunoassay
10
11

12 EULAR, European League Against Rheumatism classification criteria
13
14

15 IQR, Interquartile range
16
17

18 NRC, National Referral Center
19
20

21 SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment–
22

23 Systemic Lupus Erythematosus Disease Activity Index
24
25

26 SLE, systemic lupus erythematosus
27
28

29 SS, Sjögren's syndrome
30
31

32 SSCS, Swiss SLE Cohort Study
33
34

35 SVV, Small vessel vasculitis
36
37

38 UV, Urticarial vasculitis
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract**Objectives:**

To describe the clinical and pathological features of biopsy-proven cutaneous vasculitis (CV) associated with systemic lupus erythematosus (SLE), focusing on diagnosis classification and impact on overall SLE activity.

Methods:

Retrospective multicentric cohort study including SLE patients with biopsy-proven CV identified by 1) data from pathology departments of three university hospitals and 2) a national call for cases. SLE was defined according to 1997 revised ACR and/or 2019 ACR/EULAR criteria. CV diagnosis was confirmed histologically and classified by using the dermatological addendum of the Chapel Hill classification. SLE activity and flare severity at the time of CV diagnosis were assessed independently of vasculitis items with the SELENA-SLEDAI and SELENA-SLEDAI Flare Index.

Results:

Overall, 39 patients were included; 35 (90%) were female. Cutaneous manifestations included mostly palpable purpura (n=21; 54%) and urticarial lesions (n=18; 46%); lower limbs were the most common location (n=33; 85%). Eleven (28%) patients exhibited extracutaneous vasculitis. A higher prevalence of Sjögren's syndrome (51%) was found compared with SLE patients without CV from the French referral center group (12%, $p<0.0001$) and the Swiss SLE Cohort (11%, $p<0.0001$). CV were mostly classified as urticarial vasculitis (n=14, 36%) and cryoglobulinemia (n=13, 33%). Only 2 (5%) patients had no other cause than SLE to explain the CV. Sixty-one percent of patients had inactive SLE.

1
2
3 **Conclusion:** SLE-related vasculitis seems very rare and other causes of vasculitis should be
4 ruled out before considering this diagnosis. Moreover, in more than half of patients, CV was
5 not associated with another sign of active SLE.
6
7
8
9

10 **Keywords:** Systemic Lupus Erythematosus, Cutaneous Vasculitis, Lupus Activity, Urticarial
11 Vasculitis, Cryoglobulinemia, Sjögren Syndrome
12
13
14
15
16
17
18

19 **Key messages**

- 20
21
22 1) Only five percent of patients had no other cause than SLE to explain the CV.
23
24 2) During SLE, most of the CV were classified as UV (36%) or cryoglobulinemia-associated
25 CV (33%).
26
27 3) During CV occurrence, 61% of patients had inactive SLE and 24% had a severe flare.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Vasculitis associated with systemic lupus erythematosus (SLE) is a potentially life-threatening condition and considered a sign of activity and severity in most SLE evaluation scales, including the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) and SELENA-SLEDAI Flare Index (1–3). Few studies have estimated the prevalence of vasculitis during SLE (4–7). In these studies, the prevalence of associated vasculitis ranged from 11% and 36%, and small vessel vasculitis (SVV) of the skin accounted for the most common type observed, 82% to 89% of cases (4,5). This prevalence is probably overestimated because the cutaneous vasculitis (CV) diagnosis was based on clinical descriptions (6,7) or without skin biopsy in about 50% of cases (4,5). Indeed, in the study of Bouaziz *et al.* involving 50 SLE cases with digital involvement, vasculitis was diagnosed clinically in 18 (36%) of cases but was confirmed on skin biopsy in only two (4%) (8). Moreover, other conditions associated with SLE, such as Sjögren's syndrome (SS) and cryoglobulinemia, may also manifest as CV, which leads to difficulties in classifying SLE-associated vasculitis (9,10). In some studies, the presence of CV was reported to be associated with SLE activity (5,11,12). However, these studies did not assess whether SLE was active at the time of CV diagnosis, in particular after excluding the vasculitis item of the SELENA-SLEDAI, which may have affected the results.

Here, we performed a retrospective multicenter study to assess the clinical and immunological features as well as the causes of CV associated with SLE. We also aimed at investigating the SLE activity at CV diagnosis independent of vasculitis-related items.

Patients and methods

Patients, study design and settings

This retrospective multicentric cohort study included SLE patients with histologically proven CV occurring during SLE history. SLE was diagnosed according to the 1997 American College of Rheumatology (ACR) criteria for SLE classification and/or the 2019 ACR/European League Against Rheumatism (EULAR) classification criteria (13,14). Cases were identified by 1) the database of the pathology departments of three university hospitals in Paris (including the French National referral Center for SLE) between 2011 and 2021 using the Association pour le Développement de l'Informatique en Cytologie et Anatomopathologie (ADICAP) code 9312 (leukocytoclastic vasculitis) and 4230 (purpura with vasculitis); and 2) a national call for cases from the French Group for the Study of Systemic Diseases in Dermatology (EMSED), a group belonging to the French dermatology society. For the call for cases, an email was sent to all the members of the group in December 2019 with similar inclusion and exclusion criteria than for cases identified in our pathological database. Patients with a CV diagnosis prior to SLE diagnosis were excluded. Associated Sjögren Syndrome was defined according to ACR/EULAR 2016 (15) and Antiphospholipid Syndrome (APS) according to 2006 revised criteria (16).

This study was approved by the ethical committee of Sorbonne Université (CER2021-099), and written informed consent was obtained from all participants according to the Helsinki convention.

Definition and classification of vasculitis

The definite CV diagnosis was based on the presence of perivascular inflammatory infiltrates associated with 1) vessel wall fibrinoid necrosis and/or 2) leukocytoclasia (defined as extensive karyorrhexis of the vascular and perivascular leukocytes) on skin biopsy. Concomitant extra-

1
2
3 cutaneous vasculitis was retained only when confirmed by biopsy and/or arteriography except
4
5 for mononeuritis multiplex, which was diagnosed by nerve study conduction.
6
7

8 All cases were reviewed by 2 dermatologists, 1 internist and 1 pathologist (PB, MJ, YD and
9
10 FC). The causes of CV were classified according to the dermatological addendum of the Chapel
11
12 Hill classification (17). SLE-related CV was diagnosed when no other cause than SLE
13
14 contributing to CV was identified. Urticarial vasculitis (UV) was defined as CV presenting with
15
16 lasting (>24 hr) urticarial lesions in the absence of a specific etiology (e.g., drug-induced,
17
18 infection, sepsis or neoplasm) or serum cryoglobulinemia. Hypocomplementemic UV was
19
20 distinguished from normocomplementemic UV by the presence of hypocomplementemia (C3
21
22 and/or C4) (18). Cryoglobulinemic vasculitis was diagnosed in the presence of CV associated
23
24 with serum cryoglobulinemia estimated by centrifugation of serum at 4°C after incubation for
25
26 7 days. Sjögren Syndrome-related vasculitis was defined as non-cryoglobulinemic, non-
27
28 urticarial leukocytoclastic vasculitis, as proposed by Ramos-Casals *et al.* (10). An infection-
29
30 induced vasculitis diagnosis was considered when the onset of CV occurred within 7 days after
31
32 bacterial or viral infection with sepsis and in the absence of another specific etiology (19). A
33
34 drug-induced vasculitis diagnosis was retained with temporal association of onset with drug
35
36 intake and reversibility with discontinuation of the likely etiologic drug. When several causes
37
38 of CV were identified were available or when there was no consensus in classification, all
39
40 potential causes were indicated.
41
42
43
44
45
46
47

48 *Comparison of SLE patients with and without CV*

49

50
51 Demographics, SLE historical characteristics and main comorbidities of SLE patients with a
52
53 diagnosis of CV were compared to 345 consecutive SLE patients from the French national
54
55 referral center for SLE seen in consultation between December 2018 and 2020 after excluding
56
57 patients with a definite or suspected CV history. In order to perform a nested case control study
58
59 with a 4:1 relationship, we randomly selected 156 patients from these 345 controls using JMP
60

1
2
3 v15 (SAS Institute Inc). Moreover, the characteristics of CV patients were also compared to an
4 external cohort of 133 SLE included in the Swiss SLE Cohort Study (SSCS) (Swiss Ethics
5 review board (PB_2017-01434) seen in consultation between November 2017 and December
6 2018(20).
7
8
9

10 11 12 *SLE activity and flare severity at the time of CV diagnosis and definitions*

13
14 Demographics, SLE clinical characteristics, the SELENA–SLEDAI (1–3), routine laboratory
15 testing and immunological parameters, including C3, C4, CH50 complement levels; anti-
16 dsDNA autoantibody levels; the presence of cryoglobulinemia; and the received treatments
17 were recorded at the time of the first CV episode. Active SLE was defined with SELENA–
18 SLEDAI ≥ 6 , and SLE flares were characterized according to the SELENA-SLEDAI Flare
19 Index (2,3). To evaluate SLE activity independent of CV, both the SELENA–SLEDAI and
20 SELENA-SLEDAI Flare Index were calculating without incorporating the vasculitis item.
21 Constitutional signs include fever (defined as a body temperature above 38.5°C in absence of
22 infectious causes), weight loss (defined as a loss of at least 5% of body weight),
23 lymphadenopathy/splenomegaly and anorexia. The class of lupus nephritis was recorded
24 according to the International Society of Nephrology/Renal Pathology Society-2003 (21) and
25 hemophagocytic lymphohistiocytosis was defined according to Henter *et al.* criteria (22).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Treatment for CV and response to therapy*

45
46 The treatments used for CV were recorded, and response to therapy was assessed for patients
47 with ≥ 6 months of follow-up. Cutaneous response was classified as complete remission
48 (complete disappearance of lesions), partial response (improvement compared to baseline based
49 on the physician's opinion) or no response (no improvement or worsening of lesions). Time to
50 treatment failure was measured from the date of treatment initiation to disease relapse requiring
51 a new add-on therapy.
52
53
54
55
56
57
58
59
60

Statistical analysis

Categorical variables are expressed as number (%) and quantitative variables as mean± SD or median (interquartile [IQR]), as appropriate. The Mann–Whitney U-test or Student t-test was used for analysis of continuous data and the Fisher’s exact or chi-squared test for categorical data. All tests were two-sided and $p < 0.05$ defined significance. Statistical analyses were performed with GraphPad Prism v8.0.1 (GraphPad Software, San Diego, CA, USA),

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

The search in the database of the pathology departments using the ADICAP codes identified 522 patients with confirmed CV between 2011 and 2021; 25 (5%) had associated SLE (**Flow chart, Supplementary Figure S1**, available at *Rheumatology* online). In addition, 14 patients were included from the national call for cases.

Clinical, biological and histological CV features

Among the 39 patients included in the analysis; 35 (90%) were female and the median age at diagnosis of CV was 43 years (IQR 36-51). Clinical and pathological CV features are in **Table 1**. The main cutaneous findings included palpable purpura in 21 (54%) patients, long-lasting (>24 h) urticarial lesions in 18 (46%), erythematous papules/macules in 12 (31%), ulcerated/necrotic lesions in 8 (21%), livedo reticularis in 5 (13%) and nodular lesions in 1 (2.5%). The most common locations of cutaneous lesions were lower limbs in 33 (85%) patients, followed by trunk and/or abdomen in 13 (33%), arms in 11 (28%) and hands (fingertips and/or palms) in 8 (21%). Extracutaneous vasculitis was reported in 11 (28%) patients, mostly peripheral nerve involvement in 8 (21%) (proven by nerve biopsy, n=1) but also renal (membranoproliferative glomerulonephritis), muscular, and digestive involvement (n=1 each). Other associated manifestations included episcleritis in 3 (8%) patients and angioedema in 3 (8%).

Considering pathological features, all CV cases were classified as SVV. The main histological features included peri-vascular inflammatory cell infiltrates in all 39 patients, with predominant neutrophilic infiltrates in 22 (56%), lymphocytic infiltrates in 15 (38%) and no predominant population in 2 (5%). Overall, 33 (85%) of CV had associated leukocytoclasia, with fibrinous necrosis of the vessel wall in 20 (51%). Direct immunofluorescence assay was performed in 21/39 (54%) patients, and results were positive with perivascular deposits in 15/21 (71%), with

1
2
3 immunoreactivity to C3 in 13/21 (62%), immunoglobulin M or G in 8/21 (38%) and C1q in
4
5 5/21 (24%).
6
7

8 *SLE characteristics, activity and flare severity at time of CV diagnosis and during follow-up*

10
11 The main SLE characteristics at the first episode of CV are summarized in **Table 2**. The median
12
13 age at SLE diagnosis was 31 years (IQR 25-42). SLE was diagnosed before the occurrence of
14
15 CV in 30 (77%) patients and concomitantly in 9 (23%). The median time between SLE
16
17 diagnosis and the first CV episode was 6 years (IQR 0-19). After excluding the vasculitis item
18
19 from the SELENA-SLEDAI, at the first CV episode, SLE was active (SELENA-SLEDAI \geq 6)
20
21 in 15/38 (39%) patients. Moreover, according to the SELENA-SLEDAI Flare Index, 15/38
22
23 (39%) patients experienced a flare, classified as severe in 9/38 (24%). The most frequent active
24
25 concomitant SLE features were cutaneous lupus in 17/38 (45%), arthritis in 14/38 (37%) and
26
27 constitutional signs in 11/38 (29%) patients. Six of 38 (16%) patients had active lupus nephritis,
28
29 including class I (n=1), class III (n=1), class IV (n=2), class II+V (n=1) and class III + V (n=1)
30
31 lesions. Two of 38 (5%) patients had hemolytic autoimmune anemia and one (3%)
32
33 hemophagocytic lymphohistiocytosis.
34
35
36
37
38

39
40 Immunological findings included decreased complement C3 or C4 levels in 25/33 (76%),
41
42 increased DNA binding in 20/33 (61%) and positivity for anti-C1q antibodies in 2/9 (22%).
43
44 Overall, 15/32 (47%) patients had cryoglobulinemia, including type II (n=6), type III (n=5) and
45
46 untyped (n=4). None of the 33 patients tested were positive for anti-neutrophil cytoplasmic
47
48 autoantibodies (ANCA). Biological testing showed frequent lymphopenia (n=28/30; 93%),
49
50 anemia (n=23/33; 70%), and elevated C-reactive protein (CRP) level (n=20/33; 61%).
51
52
53

54 *Comparison of SLE patients with and without CV*

55
56
57 The median follow-up duration of the controls without CV was 13 years (IQR 7-21) for the 156
58
59 randomly selected patients from the French NRC and 9.5 (IQR 4-18) for the SSCS compared
60

1
2
3 with 15 years (9-23.5) for the 39 CV patients ($p=0.27$ and $p=0.006$ respectively). We found
4 significantly higher prevalence of SS (51%) compared with SLE patients without CV from the
5 French NRC (12%, $p<0.0001$) and the SSCS (11%, $p<0.0001$). Moreover, patients with CV
6 more frequently had a history of cutaneous lupus (92% vs. 69%; $p=0.0013$ (French NRC) and
7 vs. 54%; $p<0.0001$ (SSCS)) and decreased C3 and C4 levels during follow-up compared to
8 patients from French NRC (80% vs. 48%; $p=0.002$ and 97% vs. 47%; $p<0.0001$) (**Table 3**).
9

17 *Classification of CV*

10 All cases were reviewed by four investigators, and CV was classified by using dermatological
11 addendum of the Chapel Hill classification. In total, 29 (74%) CV cases were classified in one
12 category, mostly UV ($n=14$, 36%) and cryoglobulinemic vasculitis ($n=13$, 33%) (**Table 4**). Of
13 note, among the 13 patients with cryoglobulinemic vasculitis, $n=9$ (69%) had secondary SS.
14 Only two patients (5%) had no other cause than SLE to explain the CV and therefore cases were
15 classified as SLE-related CV.
16

17 For nine (23%) patients, there was no unique diagnosis, and CV was classified as uncertain
18 diagnosis; 5 of these patients had non-cryoglobulinemic, non-urticarial CV with coexisting SS
19 diagnosis and could therefore be classified as SLE or SS-related CV. Moreover, three patients
20 had a concomitant infection: one had pneumonia with sepsis but without bacteriological
21 identification, one had a cytomegalovirus infection and one had *Klebsiella pneumoniae*
22 infection. The latter patient also showed SLE flare concomitant to active neoplasia and type III
23 cryoglobulinemia. Finally, one patient with SLE flare presented non-typable cryoglobulinemia
24 with a very minute cryoglobulin pellet and unusual cryoglobulinemic vasculitis presentation
25 (punctate purpura and livedo reticularis limited to digits and palms) and therefore the case was
26 classified as SLE- or cryoglobulin-related CV.
27

28 *First-line treatment and CV outcomes*

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 CV treatments and follow-up data were available for 37 patients. First-line treatment consisted
4 of oral corticosteroids for 27 (73%) patients, including 16 who initially received an intravenous
5 infusion (**Table 5**). Moreover, six patients with a diagnosis of UV received antihistamines
6 therapy, and three (8%) patients received colchicine. Hydroxychloroquine was initiated for 11
7 (30%) patients, including nine with a concomitant diagnosis of SLE and two had previously
8 diagnosed SLE but undetectable HCQ blood concentration despite a prescription and were
9 therefore considered not receiving HCQ. Twenty (54%) received immunosuppressant agents.
10 When comparing treatments of patients according to SLE activity, patients with active SLE
11 independent of CV more frequently received oral corticosteroids (93% vs. 59%; $p=0.0279$).
12 After the first-line treatment, cutaneous response was classified as complete for 25 (67%)
13 patients, partial for 10 (27%) and absent for two (5%). After a median follow-up of 75 months
14 (IQR 40.5-106.5), 15 (38%) patients experienced at least one relapse at a median delay of 24
15 months (IQR 11-48). Relapses concerned patients with cryoglobulinemic vasculitis ($n=8$; 62%),
16 UV ($n=6/13$; 46%) and SLE-related vasculitis ($n=1$; 50%) (**Table 4**). No patient died from
17 vasculitis complications during the follow-up period.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In this study of 39 biopsy-proven cases of CV associated with SLE, we highlighted that SLE itself is rarely the only cause explaining CV. Most of the CV cases occurring in the setting of SLE were classified as UV (36%) or cryoglobulinemia-associated CV (33%).

Although previous studies did not specifically aim to classify CV associated with SLE, Ramos-Casals *et al.* also found a high prevalence of cryoglobulinemic vasculitis (28%) and, less frequently, UV (7%) (5). Furthermore, in our study, SLE patients with CV more frequently had a secondary SS diagnosis as compared with those with SLE without CV, which has also been suggested in other studies (11,23). Moreover, three cases had concomitant viral or bacterial infection, one with simultaneous solid organ malignancy. All these situations have been described as a possible cause of CV (17,24–26).

Regarding the clinical phenotypes of CV, previous studies identified a wide variety of cutaneous lesions, mostly erythematous punctuate lesions, palpable purpura urticarial lesions, necrosis and livedo reticularis (4–7,9,11). Some studies reported erythematous punctuate lesions of the digits as the most frequent lesions (4,5), whereas we more frequently observed palpable purpura of lower limbs, which is the most common skin manifestation of SVV (27,19). This difference could be explained by the fact that the prevalence of CV in digit lesions was overestimated in previous studies without pathological confirmation. Conversely, in our study, a skin biopsy of digital lesion may have been less frequently performed.

Previous works without systematic biopsy identified an association between CV and APS in the setting of SLE (4,5). Such association was not found in the present study and in several others (6,28). Thrombotic lesions of APS and non-vasculitic occlusive vasculopathy may be clinically misdiagnosed as CV (29,30) and thus may have contributed to an overestimation of the prevalence of CV during SLE (8).

1
2
3 As compared with previous studies (5), here we found UV as the most common diagnosis of
4 CV identified (36%). UV is a distinct clinicopathologic entity that could occur in the setting of
5
6 autoimmune diseases and mostly SLE, up to 54% of published cases (18,31,32). The Jachiet *et*
7
8 *al.* study found no significant differences between UV patients with and without SLE, except
9
10 for more frequent anti-double-stranded DNA antibodies and rheumatoid factor in the SLE group
11
12 (18). In our study, UV could occur with (38%) and without SLE flare and was often chronic,
13
14 with a significant risk of relapse (46%).
15
16
17
18
19

20 Of importance, the occurrence of CV is considered a marker of activity in several scores
21
22 including the SELENA-SLEDAI, the SELENA Flare Index (1–3), the European Consensus
23
24 Lupus Activity Measurement (ECLAM) (33) and the British Isles Lupus Assessment Group
25
26 (BILAG) (34). Furthermore, in the SLEDAI, CV is associated with high disease activity
27
28 because it scores as high as an organic brain syndrome or seizure (3). Regarding the potential
29
30 association between the occurrence of vasculitis and SLE activity, CV was found to be
31
32 associated with high disease activity (5,11,12), renal and central nervous system deterioration
33
34 (12) as well as increased Systemic Lupus International Collaborating Clinics/ACR damage
35
36 index (6,11,28). However, the association between CV and disease activity was not confirmed
37
38 in 2 studies of digital vasculitis (7,28), and no major organ involvement was associated with
39
40 CV in other studies (6,7). The assessment of SLE activity was likely biased by the inclusion of
41
42 the vasculitis item in the activity scores used in preceding works. In the present study, when
43
44 assessing SLE activity independent of the vasculitis item of the SELENA-SLEDAI, 61% of
45
46 SLE patients had inactive disease and patients with CV did not have an increased frequency of
47
48 severe SLE features included lupus nephritis or neurolupus compared with two control cohorts.
49
50 In contrast, 24% had a severe flare according to the SELENA-SLEDAI Flare index and six had
51
52 SLE renal involvement including four proliferative nephritis. SLE activity may differ according
53
54 to the etiological classification of the CV because 38% of UV cases were associated with active
55
56
57
58
59
60

1
2
3 SLE versus 2/2 (100%) of SLE-related CV but there was not enough patients to perform
4
5 statistical analyses.
6
7

8
9 The treatment of CV associated with SLE is not well codified, and only a few studies have
10
11 focused on CV management during SLE. Ramos-Casals *et al.* reported the use of oral
12
13 corticosteroids in 87% of vasculitis cases and immunosuppressant agents in 20% (cutaneous
14
15 and visceral) of cases occurring during SLE (5). In the present study, 73% of patients received
16
17 corticosteroids, including 43% with intravenous infusion, and 54% had a new
18
19 immunosuppressant agent use. Surprisingly, we found no significant difference in CV
20
21 management between patients with active and inactive SLE except for the frequency of
22
23 corticosteroids use which was higher in the active group. Particularly there was no significant
24
25 difference in the frequency of prescription of immunosuppressant treatments. We thus
26
27 hypothesized that some physicians have considered CV as an element of severity by itself even
28
29 in the absence of extra-cutaneous manifestations of lupus, notably renal or neurological
30
31 involvement. Therefore, some patients without visceral involvement or SLE flare may have
32
33 been overtreated considering that compression therapy or hydroxychloroquine or colchicine
34
35 therapy may be sufficient for UV (18) or skin-limited SVV (19,26).
36
37
38
39
40

41
42 Limitations of this work include the retrospective design and missing data. This situation
43
44 resulted in difficulties identifying the cause of CV in some patients. In particular, this study
45
46 highlights a lack of current classifications to define the origin of vasculitis in SLE associated
47
48 with SS. However, all cases were reviewed by 4 investigators with the help of the recent
49
50 dermatological addendum of the Chapel Hill classification (17), and all potential causes of CV
51
52 were indicated in doubtful cases. Moreover, some patients with definite CV may not have
53
54 undergone a skin biopsy and therefore our design did not allow for estimating the prevalence
55
56 of CV among our cohort of SLE. However, we included only biopsy-proven CV cases and
57
58 estimated the prevalence of SLE at 5% among patients with CV from 3 university hospitals,
59
60

1
2
3 which is an important finding of our study. In addition, non-specific signs or symptoms of
4 systemic inflammation, including fever, myalgia and arthralgia, could be associated with SLE
5 or SVV (27), which may have affected our assessment and potentially overestimated SLE
6 activity.
7
8
9
10
11
12

13 Overall, the occurrence of CV in the setting of SLE is rarely exclusively attributable to SLE. A
14 complete etiological work-up is necessary before concluding that CV is directly related to SLE,
15 excluding in particular SS, UV, cryoglobulinemia, and infectious and drug-induced vasculitis.
16 These results highlight that CV items should be included in activity scores of SLE activity if 1)
17 CV has been confirmed with a skin biopsy and 2) other potential causes of CV have been
18 excluded. This is important for guiding the therapeutic strategy of SLE with associated CV in
19 particular because most SLE cases are inactive after excluding the CV item in activity scores.
20 Further studies are needed to better characterize the spectrum of CV associated with SLE and
21 validate a proper classification and specific guidelines for treatment.
22
23
24
25
26
27
28
29
30
31
32
33

34 **Acknowledgements:**

35
36
37 We thank the patients, the nurses and medical staff who participated in this study.
38
39

40 We thank other members of the group “Etude des Maladies Systémiques en Dermatologie”:
41 Didier Bessis, Nadège Cordel, Dan Lipsker and Charles Cassius. We thank Camillo Ribi for
42 his involvement in the Swiss SLE Cohort Study.
43
44
45
46
47

48 **Funding:**

49
50 No specific funding was received from any bodies in the public, commercial or not-for-profit
51 sectors to carry out the work described in this article.
52
53
54
55

56 **Conflicts of interest**

57
58
59 The authors have declared no conflicts of interest.
60

Data availability statement

Data are available upon reasonable request by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). All data relevant to the study are included in the article.

References

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum.* juin 1992;35(6):630-40.
2. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med.* 21 juin 2005;142(12 Pt 1):953-62.
3. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *N Engl J Med.* 15 déc 2005;353(24):2550-8.
4. Drenkard C, Villa AR, Reyes E, Abello M, Alarcón-Segovia D. Vasculitis in systemic lupus erythematosus. *Lupus.* 1997;6(3):235-42.
5. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. *Medicine (Baltimore).* mars 2006;85(2):95-104.
6. Kallas R, Goldman D, Petri MA. Cutaneous vasculitis in SLE. *Lupus Sci Med.* sept 2020;7(1):e000411.
7. Gomes C, Carvalho JF, Borba EF, Borges CTL, Vendramini MB, Bueno C, et al. Digital vasculitis in systemic lupus erythematosus: a minor manifestation of disease activity? *Lupus.* oct 2009;18(11):990-3.
8. Bouaziz JD, Barete S, Le Pelletier F, Amoura Z, Piette JC, Francès C. Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases. *Lupus.* 1 mars 2007;16(3):163-7.
9. García-Carrasco M, Ramos-Casals M, Cervera R, Trejo O, Yagüe J, Sisó A, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. *Semin Arthritis Rheum.* avr 2001;30(5):366-73.
10. Ramos-Casals M, Anaya JM, García-Carrasco M, Rosas J, Bové A, Claver G, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. *Medicine (Baltimore).* mars 2004;83(2):96-106.
11. Gheita TA, Abaza NM, Sayed S, El-Azkalany GS, Fishawy HS, Eissa AH. Cutaneous vasculitis in systemic lupus erythematosus patients: potential key players and implications. *Lupus.* avr 2018;27(5):738-43.
12. Callen JP, Kingman J. Cutaneous vasculitis in systemic lupus erythematosus. A poor prognostic indicator. *Cutis.* nov 1983;32(5):433-6.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* sept 1997;40(9):1725.
14. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol Hoboken NJ.* sept 2019;71(9):1400-12.

15. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* Hoboken NJ. janv 2017;69(1):35-45.
16. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost JTH*. févr 2006;4(2):295-306.
17. Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheumatol* Hoboken NJ. 2018;70(2):171-84.
18. Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. The Clinical Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data From a French Nationwide Study of Fifty-Seven Patients. *Arthritis Rheumatol*. 2015;67(2):527-34.
19. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. *Am J Clin Dermatol*. 2008;9(2):71-92.
20. Chasset F, Ribi C, Trendelenburg M, Huynh-Do U, Roux-Lombard P, Courvoisier DS, et al. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. *Rheumatol Oxf Engl*. 1 nov 2020;59(11):3468-78.
21. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int*. févr 2004;65(2):521-30.
22. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer*. févr 2007;48(2):124-31.
23. Fukuda MV, Lo SC, de Almeida CS, Shinjo SK. Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus. *Clin Rheumatol*. mars 2009;28(3):301-4.
24. Lotti T, Ghersetich I, Comacchi C, Jorizzo JL. Cutaneous small-vessel vasculitis. *J Am Acad Dermatol*. nov 1998;39(5 Pt 1):667-87; quiz 688-90.
25. Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. *J Am Acad Dermatol*. févr 2012;66(2):e55-65.
26. Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. *Clin Dermatol*. oct 2006;24(5):414-29.
27. Jennette JC, Falk RJ. Small-Vessel Vasculitis. *N Engl J Med*. 20 nov 1997;337(21):1512-23.
28. Sakamoto AP, Silva CA, Silva MFC da, Lopes AS, Russo GCS, Sallum AME, et al. Initial digital vasculitis in a large multicenter cohort of childhood-onset systemic lupus erythematosus. *Rev Bras Reumatol*. déc 2017;57(6):583-9.

- 1
- 2
- 3 29. Llamas-Velasco M, Alegría V, Santos-Briz Á, Cerroni L, Kutzner H, Requena L. Occlusive
- 4 Nonvasculitic Vasculopathy. *Am J Dermatopathol.* sept 2017;39(9):637-62.
- 5
- 6 30. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid
- 7 syndrome: clinical and immunologic manifestations and patterns of disease expression in a
- 8 cohort of 1,000 patients. *Arthritis Rheum.* avr 2002;46(4):1019-27.
- 9
- 10 31. Aydogan K, Karadogan SK, Adim SB, Tunali Ş. Hypocomplementemic urticarial vasculitis: a rare
- 11 presentation of systemic lupus erythematosus. *Int J Dermatol.* 2006;45(9):1057-61.
- 12
- 13 32. Wisnieski JJ. Urticarial vasculitis. *Curr Opin Rheumatol.* janv 2000;12(1):24-31.
- 14
- 15 33. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in
- 16 systemic lupus erythematosus: report of the Consensus Study Group of the European
- 17 Workshop for Rheumatology Research. II. Identification of the variables indicative of disease
- 18 activity and their use in the development of an activity score. The European Consensus Study
- 19 Group for Disease Activity in SLE. *Clin Exp Rheumatol.* oct 1992;10(5):541-7.
- 20
- 21 34. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development
- 22 and initial validation of an updated version of the British Isles Lupus Assessment Group's
- 23 disease activity index for patients with systemic lupus erythematosus. *Rheumatol Oxf Engl.* juill
- 24 2005;44(7):902-6.
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Characteristics	
Vasculitis cutaneous features	
Palpable purpura	21 (54)
Urticarial lesions	18 (46)
Erythematous papules/macules	12 (31)
Ulcerated/necrotic lesions	8 (21)
Livedo reticularis	5 (13)
Nodular lesions	1 (2.5)
Association of lesions type	17 (44)
Topography of cutaneous lesions	
Legs/lower limbs	33 (85)
Trunk/abdomen	13 (33)
Arms/upper limbs	11 (28)
Fingertips and/or palms	8 (21)
Face	0 (0)
Association of locations	18 (46)
Associated features	
Angioedema	3 (8)
Episcleritis	3 (8)
Vasculitis visceral involvement	
Mononeuritis multiplex	8 (21)
Membranoproliferative glomerulonephritis	1 (2)
Muscle involvement	1 (2)
Digestive involvement	1 (2)
Biological and immunological features	
Elevated CRP level (>5 mg/L)	20/33 (61) ‡
Cryoglobulinemia §	15/32 (47) ‡
Anti-C1q positive	2/9 (22) ‡
ANCA-positive	0/33 (0) ‡
Histological features	
Inflammatory cell infiltration	39 (100)
predominant neutrophilic infiltrates	22 (56)
predominant lymphocytic infiltrates	15 (38)
predominant eosinophilic infiltrates	0 (0)
no predominant infiltrate	2 (5)
Leucocytoclasia	33 (85)
Vascular fibrinous necrosis	20 (51)
Direct Immunofluorescence features	
Perivascular C3 deposits	13/21 (62) ‡
Perivascular Ig deposits	8/21 (38) ‡
Perivascular C1q deposits	5/21 (24) ‡

Table 1: Clinical and histological characteristics of cutaneous vasculitis in systemic lupus erythematosus (SLE) (n=39)

Data are n (%).

‡ Positive assay/number of patients assessed.

§ n= 6 type II, n= 5 type III, n=4 untyped cryoglobulinemia

ANCA; antineutrophil cytoplasmic antibody, CRP; C-reactive protein, Ig; immunoglobulin

1		
2		
3		
4	Age at CV diagnosis, years, median (IQR)	43 (36-51)
5	SLE duration at time of CV diagnosis, years, median (IQR)	6 (0-19)
6	SLE activity at vasculitis diagnosis	
7	SELENA-SLEDAI score, median (IQR)	12 (10-17.5)
8	SELENA-SLEDAI score, median (IQR) after excluding the vasculitis item	4 (2-9.5)
9	Active SLE (SELENA-SLEDAI score \geq 6) after excluding the vasculitis	15/38 (39) ‡
10	item	
11	SLE flare excluding the vasculitis item *	15/38 (39) ‡
12	Mild/moderate flare	6/38 (16) ‡
13	Severe flare	9/38 (24) ‡
14		
15	SLE active manifestations at time of CV diagnosis	
16	Active cutaneous lupus	17/38 (45) ‡
17	Subacute cutaneous lupus	8/38 (21) ‡
18	Chronic cutaneous lupus	7/38 (18) ‡
19	Acute cutaneous lupus	4/38 (11) ‡
20	Arthritis	14/38 (37) ‡
21	Constitutional signs	11/38 (29) ‡
22	Active lupus nephritis§	6/38 (16) ‡
23	Hemolytic autoimmune anemia	2/38 (5) ‡
24	Active lupus serositis	1/38 (3) ‡
25	Hemophagocytic lymphohistiocytosis	1/38 (3) ‡
26	Active neuropsychiatric lupus	0/38 (0) ‡
27	Immune thrombocytopenia	0/38 (0) ‡
28		
29	Biological and immunological features	
30	Increased DNA binding (above normal range for testing laboratory)	20/33 (61) ‡
31	Low C3 level	20/35 (57) ‡
32	Low C4 level	25/33 (76) ‡
33	Leucopenia (<3 G/L)	6/31 (19) ‡
34	Lymphopenia (<1.5 G/L)	28/30 (93) ‡
35	Anemia	23/33 (70) ‡
36	Thrombocytopenia (<100 G/L)	0/33 (0) ‡
37		
38	Associated disease	
39	Concomitant infection #	3 (8)
40	Active Neoplasia ##	1 (3)

Table 2. Main features of SLE at diagnosis of cutaneous vasculitis (CV) (n=39)

Data are n (%), unless stated otherwise.

‡ Positive assay/number of patients with available data.

* Defined using SELENA-SLEDAI Flare Index

§ including class I (n=1), class III (n=1), class IV (n=2), class II+V (n=1) and class III + V (n=1) lesions according to ISN/RPS-2003.

1 *Klebsiella pneumoniae* pneumonia with sepsis, 1 pneumonia with sepsis (no microbiological identification), 1 primo CMV infection.

Adenocarcinoma of the lung; this patient also had bacterial pneumonia and type 3 cryoglobulinemia

DNA, deoxyribonucleic acid; IQR, interquartile range; ISN, International Society of Nephrology; RSP, Renal Pathology Society; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index; SLE, systemic lupus erythematosus.

	SLE with CV (n = 39) n (%)	Control group (French NRC) (n = 156) n (%)	p value^a	Control group (SSCS) (n = 133) n (%)	p value^b
Women	35 (90)	142 (91)	0.76	111 (83)	0.44
Age at SLE diagnosis, years, median (IQR)	31 (25-42)	25 (18-34)	0.001	32 (23-44)	0.73
Follow-up duration, years, median [IQR]	15 (9-23.5)	13 (7-21)	0.27	9.5 (4-18)	0.006
<i>Other autoimmune diseases</i>					
Sjogren's syndrome	20 (51)	19 (12)	<0.0001	15 (11)	<0.0001
Antiphospholipid syndrome	6 (15)	17 (11)	0.41	8 (6)	0.09
<i>Historical SLE clinical features</i>					
Lupus arthritis	37 (95)	145 (93)	1	98/132 (74)‡	0.004
Cutaneous lupus (except CV)	36 (92)	107 (69)	0.002	72 (54)	<0.0001
Lupus nephritis	16 (41)	61 (39)	0.86	50/131 (38)‡	0.85
Constitutional signs	15 (38)	51 (33)	0.57		
Cytopenia (except isolated lymphopenia)	15 (38)	51 (33)	0.57	NA	-
Lupus serositis	10 (26)	32 (20)	0.51	43 (32)	0.55
Neuropsychiatric (except vasculitis-related)	2 (5)	16 (10)	0.53	18 (13)	0.25
<i>Immunological parameters(ever)</i>					
Increased DNA binding (ELISA)	34 (87)	149 (95)	0.07	89/132 (67)‡	0.01
Low C3 level	31 (80)	70/145 (48)‡	0.0005	NA	-
Low C4	38 (97)	80/145 (55)‡	<0.0001	NA	-

Table 3: Main historical features of 39 SLE patients with CV and control groups

Data are n (%), unless stated otherwise.

‡ Positive assay/number of patients assessed.

^a Estimated by comparing SLE patients with CV to 156 randomly selected SLE controls without CV from the French NCR for Lupus.

^b Estimated by comparing SLE patients with CV to the 133 SLE included in the Swiss SLE cohort

CV, cutaneous vasculitis; ELISA, enzyme-linked immunoassay; NRC, National Referral Center; IQR, Interquartile range; NA, Non Assessable; SLE, systemic lupus erythematosus; SSCS, Swiss SLE Cohort Study

Variables with P<0.05 on univariate analysis are highlighted in bold

	Patients n (%)	Female n (%)	Visceral involvement n (%)	Active SLE n (%)	Predominant cutaneous lesions (%)	Predominant locations (%)	Relapse n (%)	Delay before relapse, median (IQR), months
Retained diagnosis								
Urticarial vasculitis§	14 (36)	14 (100)	1 (7)	5/13 (38)	urticarial lesions (100), palpable purpura (29)	legs (86), trunk/abdomen (71), arms (57), palms/digits (14)	6/13 (46)	36 (16-49)
Cryoglobulinemic vasculitis	13 (33)	12 (92)	7 (54)	3 (23)	palpable purpura (77), ulcero-necrotic (31), urticarial lesions (23)	legs (85), arms (15), palms/digits (15)	8 (62)	24 (10-63)
SLE-related vasculitis	2 (5)	2 (100)	0 (0)	2 (100)	palpable purpura (100)/erythematous macules or papules (50)	legs (100)	1 (50)	11
Drug-induced vasculitis†	1 (3)	1 (100)	0 (0)	0 (0)	urticarial lesions	trunk and abdomen	0 (0)	/
Uncertain diagnosis								
SLE or Sjögren's syndrome-related vasculitis	5 (13)	3 (60)	3 (60)	2 (40)	palpable purpura (80), erythematous macules and papules (20)	legs (100), palms/digits (20)	0 (0)	/
SLE with concomitant infection*	2 (5)	2 (100)	0 (0)	1 (50)	ulcerations (100), necrosis (50), erythematous macules and papules (50)	palms (100), arms (50), legs (50)	0 (0)	/
SLE with concomitant infection, neoplasia and cryoglobulinemia**	1 (3)	0 (0)	0 (0)	1 (100)	erythematous macules and papules with ulcerations	legs	0 (0)	/
SLE or cryoglobulinemic-related vasculitis	1 (3)	1 (100)	0 (0)	1 (100)	palpable purpura and livedo reticularis	palms and digits	0 (0)	/

Table 4. Diagnosis classification of CV in 39 patients with SLE

§ Including n=10 hypocomplementemic urticarial vasculitis, n=1 normocomplementemic urticarial vasculitis and n=3 non-classifiable (insufficient data)

† Related to rituximab injection (serum sickness syndrome)

* One pneumonia with sepsis (no bacterial identification) and one primo-cytomegalovirus infection

** SLE flare with type III cryoglobulinemia associated with *Klebsiella pneumonia* infection revealing lung carcinoma

IQR, interquartile range; SLE, systemic lupus erythematosus

First-line treatment	Total (n=38)	Active SLE (n=15)	Inactive SLE (n=23)	p value ^a
Prednisone introduced or increased	27/37 (73) #	14 (93)	13/22 (59) ‡	0.03
Prednisone, mg/day, median [IQR]	20 [3.5-60]	50 [10;60]	20 [0;60] ‡	0.09
Intravenous methylprednisolone bolus	16/37 (43) ‡	8 (53)	8/22 (36) ‡	0.33
Hydroxychloroquine	11/37 (30) ‡†	5 (33)	6/22 (27) ‡	0.73
Colchicine	3/37 (8) ‡	1 (7)	2/22 (9) ‡	1
Antihistamines	6/37 (16) ‡	1 (7)	5/22 (23) ‡	0.37
Immunosuppressive treatment	20/37 (54) ‡	11 (73)	9/22 (41) ‡	0.09
Rituximab	6/37 (16) ‡	2 (13)	4/22 (18) ‡	1
Mycophenolate mofetil	6/37 (16) ‡*	4 (27)	2/22 (9) ‡	0.19
Methotrexate	4/37 (11) ‡	2 (13)	2/22 (9) ‡	1
Azathioprine	3/37 (8) ‡	2 (13)	1/22 (4) ‡	0.55
Cyclophosphamide	2/37 (5) ‡	1 (7)	1/22 (4) ‡	1
Belimumab	1/37 (3) ‡	1 (7)	0/22 (0) ‡	0.40
Baricitinib	1/37 (3) ‡	1 (7)	0/22 (0) ‡	0.40

Table 5. Therapeutic management of CV in SLE patients

Data are n (%), unless stated otherwise.

‡ Positive /number of patients evaluated

Active SLE was defined according to SELENA-SLEDAI score ≥ 6 after excluding the vasculitis item

Prednisone introduction or increase was associated with immunosuppressant treatment (excluding antimalarials and colchicine) in 17.

† Nine patients had a diagnosis of SLE simultaneously with CV and two had previously diagnosed SLE but undetectable HCQ blood concentration despite a prescription and were therefore considered not receiving HCQ. All but one received another treatment in addition to hydroxychloroquine.

* Two patients received rituximab followed by mycophenolate mofetil. One received cyclophosphamide followed by mycophenolate mofetil.

a: comparing active SLE to inactive SLE patient

IQR, interquartile range; SLE, systemic lupus erythematosus

Variables with $P < 0.05$ on univariate analysis are highlighted in bold